Postdoctoral fellow Gina Wang at Harvard’s Wyss Institute is helping to develop a first-of-its-kind device that could one day transform how amyotrophic lateral sclerosis (ALS) is monitored and potentially diagnosed.
As part of the NERVE Validation Project, Wang is working on ultra-sensitive technology to detect abnormal RNA molecules inside extracellular vesicles – tiny particles in blood and other body fluids that carry proteins and RNA linked to disease. Because current diagnostic tools cannot «see» ALS-related RNA splicing defects, drug developers lack a precise way to tell whether their treatments are hitting the right targets.
Wang’s device aims to fill...